Inflectra biosimilar infliximab-dyyb regulatory update

FDA approved a BLA from Celltrion for Inflectra infliximab-dyyb, a biosimilar of Remicade infliximab from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.).

Read the full 286 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE